Patents by Inventor Curt HAFFNER

Curt HAFFNER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD38 inhibitors and methods of treatment
    Patent number: 9840496
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 12, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: J. David Becherer, Rodolfo Cadilla, David Norman Deaton, Curt Haffner, Brad Richard Henke, Frank Preugschat, Christie Schulte
  • CD38 INHIBITORS AND METHODS OF TREATMENT
    Publication number: 20170260164
    Abstract: Compounds of Formula I and methods of treating diseases of metabolism by modulating cellular NAD+ levels through the inhibition of the CD38 enzyme, are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 14, 2017
    Inventors: J. David BECHERER, Rodolfo CADILLA, David Norman DEATON, Curt HAFFNER, Brad Richard HENKE, Frank PREUGSCHAT, Christie SCHULTE
  • SELECTIVE RXR LIGANDS
    Publication number: 20070099991
    Abstract: The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR?, RXR?, or RXR?. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.
    Type: Application
    Filed: December 21, 2006
    Publication date: May 3, 2007
    Inventors: Curt HAFFNER, Istvan Kaldor, Darryl McDougald, Aaron Miller